»áÕ¹Ãû³Æ | 2012ÄêѪ¹ÜÉú³ÉÊõÖÎÁÆÓ¦ÓÃÑÐÌֻᣨABSTA£© |
²¼Õ¹Ê±¼ä | 2012Äê1ÔÂ15ÈÕ |
Õ¹ÀÀʱ¼ä | 2012Äê1ÔÂ16ÈÕ—2012Äê1ÔÂ21ÈÕ |
³·Õ¹Ê±¼ä | 2012Äê1ÔÂ22ÈÕ |
ËùÔÚµØÖ· |
ÃÀ¹ú °¢¶ûËþ |
»áÕ¹³¡¹Ý | snowbird¸ßɽ»¬Ñ©³¡ |
²Î»á×¢²á·Ñ | ¿ÉÒÔ. »áÔ±/·Ç»áÔ±715ÃÀÔª ·þÎñ·Ñ300ÈËÃñ±Ò/ÈË |
´úËÍǩ֤ | ¿ÉÒÔ. ·þÎñ·Ñ500ÈËÃñ±Ò/ÈË |
´ú¶©»úƱ | ¿ÉÒÔ. ÇëÓë¿Í·þÈËÔ±ÁªÏµ |
´ú¶¨Õ¹Î» |
²»¿ÉÒÔ |
´ú¶¨¾Æµê |
¿ÉÒÔ. ·þÎñ·ÑΪ×Ü·ÑÓÃ15% |
»áÕ¹ÃèÊö |
Much progress has been made in the identification of key signaling pathways regulating blood vessel development. There is also evidence that various stromal cell types participate in normal and pathological angiogenesis in a tissue- or context-specific fashion. However, many important molecular and biological questions regarding these processes remain unanswered. In addition, several angiogenesis inhibitors have been approved by the FDA as therapy for cancer or intraocular neovascular disorders. Perhaps some of the most successful applications of anti-angiogenic therapy are in age-related macular degeneration and other intraocular neovascular diseases, although such findings have been rarely presented outside specialized meetings. The Keystone Symposia meeting on Angiogenesis: Advances in Basic Science and Therapeutic Applications will critically examine the latest basic science on the regulation of angiogenesis in health and disease, discuss the lessons from clinical trials in cancer and intraocular neovascular disorders and identify novel therapeutic targets. Additional discussion will focus on a renewed interest in therapeutic angiogenesis by tissue engineering or stem cell-based approaches. ÔÚÈ·¶¨¹Ø¼üµÄÐźÅͨ·µ÷½ÚѪ¹ÜµÄ·¢Õ¹£¬ÒѾȡµÃÁ˺ܴó½øÕ¹¡£»¹ÓÐÖ¤¾Ý±íÃ÷£¬¸÷ÖÖ»ùÖÊϸ°ûÔÚÕý³£ºÍ²¡ÀíµÄѪ¹ÜÉú³ÉÔÚÒ»¸ö×éÖ¯»òÉÏÏÂÎÄÌØ¶¨µÄ·½Ê½²ÎÓ롣Ȼ¶ø£¬¹ØÓÚÕâЩ½ø³ÌµÄÐí¶àÖØÒªµÄ·Ö×ÓÉúÎïѧºÍÉúÎïÎÊÌâÈÔȻûÓд𰸡£´ËÍ⣬һЩѪ¹ÜÉú³ÉÒÖÖÆ¼ÁÒѱ»FDAÅú×¼×÷ΪÖÎÁư©Ö¢»òÑÛÄÚÐÂÉúѪ¹ÜÐÔ¼²²¡¡£Ò²ÐíһЩ×î³É¹¦µÄÓ¦Óÿ¹Ñª¹ÜÉú³ÉÖÎÁƵÄÄêÁäÏà¹ØÐԻư߱äÐÔºÍÆäËûÑÛÄÚÐÂÉúѪ¹ÜÐÔ¼²²¡£¬ËäÈ»ÕâÑùµÄ½á¹ûÒѾºÜÉÙÒÔÍâµÄרÃÅ»áÒéÌá³öµÄ¡£¶ÔѪ¹ÜÉú³ÉµÄÌÝÐÎרÌâÌÖÂÛ»á»áÒ飺ÔÚ»ù´¡¿ÆÑ§ºÍÖÎÁÆÓ¦ÓõĽøÕ¹½«×ÐϸÑо¿ÔÚ½¡¿µºÍ¼²²¡µÄѪ¹ÜÉú³ÉµÄµ÷¿ØÉÏ×îеĻù±¾µÄ¿ÆÑ§£¬ÌÖÂÛÔÚÖ×ÁöºÍÑÛÄÚÐÂÉúѪ¹ÜÐÔ¼²²¡µÄÁÙ´²ÊÔÑéµÄ¾Ñé½Ìѵ£¬È·¶¨ÐµÄÖÎÁưе㡣ÆäËûµÄÌÖÂÛ½«¼¯ÖÐÓÚÔÚÖÎÁÆÐÔѪ¹ÜÉú³ÉµÄеÄ×éÖ¯¹¤³Ì¸Éϸ°ûΪ»ù´¡µÄ·½·¨µÄÐËȤ¡£ |
Õ¹»áÖÜÆÚ |
ÿÄêÒ»½ì¡¡ |
×¢ÒâÊÂÏî |
1.ÒÔÉϱê×¢"¿ÉÒÔ"µÄ·þÎñÏîÄ¿¿Éµ¥¶À°ìÀí. |
ÔÚÏß×Éѯ | |
ÓÑÇéÌáʾ |
»ãÂʼÆËãÒÔ¸¶¿îʱÖйú¹¤ÉÌÒøÐÐÍâ»ãÂô³ö¼ÛΪ׼. |
ÁªÏµ·½Ê½ |
×Éѯµç»°: 8610-66054455 8610-51294800 ÉèËߵ绰: 8610-66054488 |